Antares Pharma Overview
- Year Founded
-
1979
- Status
-
Acquired/Merged
- Employees
-
203
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.05B
Antares Pharma General Information
Description
Developer of pharmaceutical products intended to serve the rheumatology, urology, endocrinology, and neurology sectors. The company offers testosterone enanthate injections, testosterone undecanoate capsules, epinephrine injections, and proprietary auto injector devices, enabling patients to receive medications through advanced delivery formats that improve safety and efficacy. and treatment adherence.
Contact Information
Website
www.antarespharma.comCorporate Office
- 100 Princeton South
- Suite 300
- Ewing, NJ 08628
- United States
Corporate Office
- 100 Princeton South
- Suite 300
- Ewing, NJ 08628
- United States
Antares Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 20. Merger/Acquisition | 24-May-2022 | $1.05B | Completed | Profitable | ||
| 19. Debt Refinancing | 12-Nov-2021 | Completed | Profitable | |||
| 18. PIPE | 03-Oct-2012 | Completed | Generating Revenue | |||
| 17. Secondary Transaction - Open Market | 01-Sep-2007 | Completed | Generating Revenue | |||
| 16. PIPE | 23-Jun-2007 | Completed | Generating Revenue | |||
| 15. Debt - General | 28-Feb-2007 | Completed | Generating Revenue | |||
| 14. PIPE | 23-Feb-2004 | Completed | Generating Revenue | |||
| 13. PIPE | 08-Jul-2003 | Completed | Generating Revenue | |||
| 12. PIPE | 15-Jul-2002 | $700K | $28.7M | Completed | Generating Revenue | |
| 11. PIPE | 06-Mar-2001 | $10M | $28M | Completed | Generating Revenue |
Antares Pharma Comparisons
Industry
Financing
Details
Antares Pharma Competitors (12)
One of Antares Pharma’s 12 competitors is Enable Injections, a Venture Capital-Backed company based in Cincinnati, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enable Injections | Venture Capital-Backed | Cincinnati, OH | ||||
| Nemera | Private Equity-Backed | Lyon, France | ||||
| QuVa Pharma | Private Equity-Backed | Sugar Land, TX | ||||
| CNBX Pharmaceuticals | Corporation | Bethesda, MD | ||||
| Lipocine | Corporation | Salt Lake City, UT |
Antares Pharma Patents
Antares Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4496575-A1 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | Pending | 21-Mar-2022 | ||
| EP-4496575-A4 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | Pending | 21-Mar-2022 | ||
| US-12102643-B2 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | Active | 21-Mar-2022 | ||
| US-12521404-B2 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | Active | 21-Mar-2022 | ||
| US-20230302016-A1 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | Active | 21-Mar-2022 | A61K31/573 |
Antares Pharma Signals
Antares Pharma Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amarin Corporation | Corporation | Minority | ||
| Aventic Partners | PE/Buyout | Minority | ||
| Becton, Dickinson and Company | Corporation | Minority | ||
| Calvert Research and Management | Impact Investing | Minority | ||
| Cherry Tree & Associates | Investment Bank | Minority |
Antares Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
25.11 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Antares Pharma FAQs
-
When was Antares Pharma founded?
Antares Pharma was founded in 1979.
-
Where is Antares Pharma headquartered?
Antares Pharma is headquartered in Ewing, NJ.
-
What is the size of Antares Pharma?
Antares Pharma has 203 total employees.
-
What industry is Antares Pharma in?
Antares Pharma’s primary industry is Drug Delivery.
-
Is Antares Pharma a private or public company?
Antares Pharma is a Private company.
-
What is the current valuation of Antares Pharma?
The current valuation of Antares Pharma is .
-
What is Antares Pharma’s current revenue?
The current revenue for Antares Pharma is .
-
How much funding has Antares Pharma raised over time?
Antares Pharma has raised $158M.
-
Who are Antares Pharma’s investors?
Amarin Corporation, Aventic Partners, Becton, Dickinson and Company, Calvert Research and Management, and Cherry Tree & Associates are 5 of 14 investors who have invested in Antares Pharma.
-
Who are Antares Pharma’s competitors?
Enable Injections, Nemera, QuVa Pharma, CNBX Pharmaceuticals, and Lipocine are some of the 12 competitors of Antares Pharma.
-
When was Antares Pharma acquired?
Antares Pharma was acquired on 24-May-2022.
-
Who acquired Antares Pharma?
Antares Pharma was acquired by Halozyme Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process